Prana receives Orphan Drug designation

The Food and Drug Administration granted Orphan Drug designation to Prana Biotechnolgy Ltd.'s (Nasdaq: PRAN) Huntington Disease treatment PBT2 lifting the stock price 37 cents to $2.51.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.